Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Operations (2021 - 2025)

Amylyx Pharmaceuticals has reported Cash from Operations over the past 5 years, most recently at 27903000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 27903000.0 for Q4 2025, up 52.71% from a year ago — trailing twelve months through Dec 2025 was 123343000.0 (up 26.43% YoY), and the annual figure for FY2025 was 123343000.0, up 26.43%.
  • Cash from Operations for Q4 2025 was 27903000.0 at Amylyx Pharmaceuticals, up from 30368000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for AMLX hit a ceiling of 13551000.0 in Q4 2023 and a floor of 66580000.0 in Q2 2024.
  • Median Cash from Operations over the past 5 years was 28073500.0 (2021), compared with a mean of 26687050.0.
  • Biggest five-year swings in Cash from Operations: skyrocketed 127.27% in 2023 and later tumbled 8043.97% in 2025.
  • Amylyx Pharmaceuticals' Cash from Operations stood at 28244000.0 in 2021, then crashed by 75.96% to 49697000.0 in 2022, then surged by 127.27% to 13551000.0 in 2023, then crashed by 535.45% to 59008000.0 in 2024, then surged by 52.71% to 27903000.0 in 2025.
  • The last three reported values for Cash from Operations were 27903000.0 (Q4 2025), 30368000.0 (Q3 2025), and 25248000.0 (Q2 2025) per Business Quant data.